AUTHORS
Sima Rozati, MD PhD, David Sidransky, MD2, Christiane Langer, MD3, Ohad S Bentur, MD4, Reuven Chantre, MD5
AFFILIATIONS
1 Johns Hopkins University, Baltimore, Maryland, United States
2 Johns Hopkins University, Baltimore, Maryland, United States
3 Secura Bio, Inc., Berkeley Heights, New Jersey, United States
4 Secura Bio, Inc., Berkeley Heights, New Jersey, United States
5 Secura Bio, Inc., Berkeley Heights, New Jersey, United States
ABSTRACT
Background and significance
Mycosis fungoides (MF), the most common subtype of cutaneous T-cell lymphoma, is characterized by persistent, often progressive patches and plaques that can significantly impair quality of life due to pruritus, visible disease burden, and psychosocial impact. In early-stage MF, skin-directed therapies are the standard of care; however, options are limited, and responses and duration of response are variable and do not alter long-term disease course.
Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-δ and -γ signaling pathways implicated in malignant T-cell survival and tumor microenvironment regulation. Targeting PI3K signaling represents a rational therapeutic strategy in MF. A topical gel formulation of duvelisib is being developed to enable localized delivery to skin lesions while minimizing systemic exposure and associated toxicity.
This is the first clinical study to evaluate a topical PI3K-δ/γ inhibitor in patients with early-stage MF, representing a novel approach to skin-directed therapy.
Study design and methods:
This is a phase 1, open-label, single-arm, dose-escalation study evaluating topical duvelisib gel in patients with early-stage MF.
Approximately 30 adult patients with stage IA–IIA disease and 3–5 treatment-accessible lesions will be enrolled at a single center in the United States.
Topical duvelisib will be evaluated at 3 dose levels (0.5%, 2.5%, and 5.0%) using a standard 3+3 dose-escalation design. Treatment is administered once daily for 14 days, followed by escalation to twice-daily dosing if tolerated, in 28-day cycles for up to 3 cycles. Target lesions will be limited to ≤5% of the body surface area.
The primary objectives are to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Dose escalation decisions are guided by dose-limiting toxicities observed during the first treatment cycle and reviewed by a Safety Monitoring Committee.
Secondary objectives include characterization of systemic pharmacokinetics to confirm minimal systemic exposure, and evaluation of preliminary efficacy, including local lesion response rate and global response based on modified Composite Assessment of Index Lesion Severity and modified Severity-Weighted Assessment Tool scores.
Exploratory objectives include imaging-based lesion assessment, biomarker analyses from serial skin biopsies, and patient-reported outcomes assessing symptom burden and quality of life.
Key eligibility criteria include adults with stage IA–IIA MF without clinically significant lymphadenopathy, and adequate organ function. Key exclusion criteria include advanced MF, concurrent systemic or topical MF therapy, and prior PI3K inhibitor exposure.
Trial status:
Ongoing (NCT07714187); enrollment is in progress.
DISCLOSURES
Reuven Chantre, MD: Secura Bio - Current Employment